Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings Inc (XERS) is a biopharmaceutical innovator developing ready-to-use therapies for complex conditions in endocrinology, neurology, and gastroenterology. This page aggregates official company announcements, regulatory milestones, and research developments for stakeholders tracking its progress.
Access timely updates on XERS' FDA-approved products including Gvoke (severe hypoglycemia), Recorlev (Cushing's Syndrome), and proprietary formulation platforms like XeriSol and XeriJect. Our curated news feed covers clinical trial results, partnership announcements, manufacturing updates, and financial disclosures essential for understanding the company's trajectory in advanced biotherapeutics.
This resource serves investors and healthcare professionals needing verified information about XERS' patient-centric solutions. Content is organized chronologically with clear sourcing to facilitate efficient research. Bookmark this page for structured access to earnings reports, regulatory filings, and scientific advancements from one of biopharma's most innovative formulation specialists.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) will report its third quarter 2021 financial results on November 10, 2021, before the U.S. markets open. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company develops therapies in endocrinology, neurology, and gastroenterology, with products like Gvoke® and Keveyis®. Interested parties can pre-register for the call via the provided link, and a replay will be available until November 24, 2021.
Xeris Biopharma Holdings (Nasdaq: XERS) announced a collaboration with Merck to explore the licensing of its XeriJect™ technology for ultra-high concentration monoclonal antibodies. Although financial terms were not disclosed, this collaboration aims to improve the delivery of large molecules and is part of Xeris' ongoing partnerships with major pharmaceutical companies. Xeris highlighted the importance of its product portfolio, including commercialized therapies Gvoke® and Keveyis®, and a robust pipeline, indicating a solid financial position bolstered by a $50 million synergy from the Strongbridge acquisition.
Xeris Pharmaceuticals has successfully completed its acquisition of Strongbridge Biopharma, creating Xeris Biopharma Holdings. The deal values Strongbridge at approximately
Xeris Pharmaceuticals (NASDAQ: XERS) announced the grant of restricted stock units totaling 28,750 shares to 20 new employees as part of its Inducement Equity Plan, effective October 1, 2021. This plan incentivizes new hires not previously employed by Xeris, adhering to NASDAQ rules. The stock options will vest over four years, contingent on continued employment. Xeris is focused on innovative drug formulations, including its first commercial product, Gvoke, utilizing room-temperature stable formulations to enhance patient and healthcare provider experiences.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced that CEO Paul R. Edick will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 8:15 a.m. ET. The presentation can be accessed via the company's website. Xeris focuses on developing ready-to-use injectable drug formulations using its proprietary XeriSol™ and XeriJect™ technologies, which aim to simplify therapy administration and improve patient experiences. Xeris is headquartered in Chicago, IL.
Xeris Pharmaceuticals (XERS) has received overwhelming approval from its stockholders for the acquisition of Strongbridge Biopharma (SBBP). At a special meeting on September 14, 2021, approximately 97% of shares voted in favor, equating to about 59% of Xeris' total outstanding shares. The acquisition, set to close in early October 2021, will merge the businesses under Xeris Biopharma Holdings, Inc. This strategic move aims to strengthen Xeris' position in endocrinology and neurology, leveraging a differentiated technology platform to address unmet patient needs.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced that CEO Paul R. Edick will present an overview of the company during the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting September 13, 2021, at 6:00 a.m. ET, accessible through the Investors section of the company’s website.
Xeris focuses on developing ready-to-use injectable drug formulations, including its first product, Gvoke®, leveraging innovative technologies for stability and ease of use.
Xeris Pharmaceuticals (NASDAQ: XERS) announced the successful enrollment and dosing of participants in a Phase 1 study of XP-8121, a novel subcutaneous formulation of levothyroxine for hypothyroidism. This study aims to evaluate pharmacokinetics, safety, and tolerability, with results expected in Q1 2022. Preliminary data suggest XP-8121 may overcome challenges associated with oral levothyroxine, such as dosage variability and medication adherence. The study involves 30 healthy participants and is conducted in partnership with Celerion.
Xeris Pharmaceuticals (Nasdaq: XERS) announced the FDA approval of its supplemental new drug application (sNDA) for the Gvoke® Kit, a ready-to-use injectable drug formulation for treating severe hypoglycemia in diabetes patients aged 2 and above. The Gvoke Kit will include a 1 mg/0.2 mL single-dose vial and syringe kit, enhancing patient convenience by eliminating the need for reconstitution. Manufacturing will commence immediately, with availability expected early in Q1 2022. The approval was backed by a pharmacokinetic study showing bioequivalence to the pre-filled syringe formulation.
Xeris Pharmaceuticals (Nasdaq: XERS) has announced the grant of three new patents concerning its formulation technologies. The U.S. Patent and Trademark Office issued U.S. Patent Nos. 10,987,399 and 11,020,403, covering storage-stable formulations of pramlintide and benzodiazepines, respectively. Additionally, the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 for pre-filled syringes utilizing Xeris’ XeriJect™ technology. These patents expand Xeris’ intellectual property portfolio, now totaling 121 patents worldwide, supporting innovation in therapies for diabetes and other conditions.